Active	Status	Sponsor type	Region	Phase	Filter
5 Active 7 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jemec, Gregor BE
OSIRIS, NCT04982432 / 2021-000049-42: Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa	Not yet recruiting	2	24	NA	Orismilast, UNI5001	Gregor Jemec, UNION therapeutics	Hidradenitis Suppurativa	12/22	12/22
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Terminated	2	72	Europe, Canada, US, RoW	Placebo, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	05/25	05/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jemec, Gregor BE
OSIRIS, NCT04982432 / 2021-000049-42: Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa	Not yet recruiting	2	24	NA	Orismilast, UNI5001	Gregor Jemec, UNION therapeutics	Hidradenitis Suppurativa	12/22	12/22
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus	Terminated	2	72	Europe, Canada, US, RoW	Placebo, Daxdilimab, HZN-7734	Amgen, Horizon Therapeutics Ireland DAC	Discoid Lupus Erythematosus	05/25	05/25